Key Points
- Katie Bickerstaffe bought 352 Diploma shares at an average of GBX 5,645 on Jan 14, a total open‑market purchase of £19,870.40.
- Board‑level buying (Bickerstaffe and non‑exec Ian El‑Mokadem) alongside a reported 14% organic revenue jump in Q1 and raised M&A guidance underline management confidence in the firm's growth outlook.
- Analysts are broadly positive — including a Deutsche Bank upgrade to a GBX 6,200 target — with a consensus price target around GBX 5,634; the stock trades at roughly a P/E of 41x and a market cap of about £7.6bn.
Diploma PLC (LON:DPLM - Get Free Report) insider Katie Bickerstaffe purchased 352 shares of the company's stock in a transaction that occurred on Wednesday, January 14th. The shares were purchased at an average cost of GBX 5,645 per share, for a total transaction of £19,870.40.
Diploma Trading Up 2.0%
LON:DPLM opened at GBX 5,665 on Friday. The company has a debt-to-equity ratio of 62.17, a quick ratio of 0.80 and a current ratio of 2.17. The firm has a market cap of £7.60 billion, a price-to-earnings ratio of 41.26, a price-to-earnings-growth ratio of 2.82 and a beta of 0.75. Diploma PLC has a 52 week low of GBX 3,532 and a 52 week high of GBX 5,760. The firm has a 50-day moving average price of GBX 5,411.02 and a two-hundred day moving average price of GBX 5,351.16.
Diploma (LON:DPLM - Get Free Report) last announced its earnings results on Monday, December 8th. The company reported GBX 176 earnings per share for the quarter. Diploma had a return on equity of 13.18% and a net margin of 9.25%. On average, equities analysts expect that Diploma PLC will post 163.7995512 earnings per share for the current fiscal year.
Trending Headlines about Diploma
Here are the key news stories impacting Diploma this week:
- Positive Sentiment: Q1 trading: Diploma reported a 14% jump in organic revenue for Q1 and raised its M&A guidance, which underpins the firm's growth story and supports higher forward earnings expectations. Investing.com article
- Positive Sentiment: Analyst upgrade: Deutsche Bank raised its price target from GBX 6,000 to GBX 6,200 and set a "buy" rating, signaling stronger sell-side conviction and providing a clear upside reference for investors. Digital Look broker note
- Positive Sentiment: Board-level buying: Non-executive directors Ian El‑Mokadem and Katie Bickerstaffe have increased their personal holdings, a vote of confidence from the board that reduces governance-related uncertainty. TipRanks announcement
- Positive Sentiment: Insider purchases: Two insiders made open-market buys (Ian El‑Mokadem ~500 shares at ~GBX 5,615; Katie Bickerstaffe ~352 shares at ~GBX 5,645), reinforcing management/board confidence in the share price. MarketBeat filings
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on DPLM shares. Royal Bank Of Canada upgraded shares of Diploma to an "outperform" rating and increased their price target for the company from GBX 4,500 to GBX 6,000 in a research report on Friday, October 3rd. Peel Hunt reaffirmed a "buy" rating and set a GBX 6,150 price objective on shares of Diploma in a report on Friday, December 19th. Berenberg Bank reiterated a "buy" rating and issued a GBX 6,350 target price on shares of Diploma in a research note on Wednesday, November 19th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Diploma from GBX 6,000 to GBX 6,200 and gave the company a "buy" rating in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of GBX 5,634.29.
View Our Latest Report on DPLM
About Diploma
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
